Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $215.9 million.

  • Ocular Therapeutix's Shares Outstanding rose 3688.01% to $215.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $215.9 million, marking a year-over-year increase of 3688.01%. This contributed to the annual value of $215.9 million for FY2025, which is 3688.01% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Shares Outstanding stood at $215.9 million, which was up 3688.01% from $174.9 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Shares Outstanding high stood at $215.9 million for Q4 2025, and its period low was $76.2 million during Q1 2021.
  • Its 5-year average for Shares Outstanding is $115.6 million, with a median of $79.3 million in 2023.
  • As far as peak fluctuations go, Ocular Therapeutix's Shares Outstanding surged by 52.66% in 2022, and later surged by 9957.53% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Shares Outstanding stood at $76.7 million in 2021, then grew by 0.61% to $77.2 million in 2022, then soared by 48.91% to $115.0 million in 2023, then soared by 37.22% to $157.7 million in 2024, then soared by 36.88% to $215.9 million in 2025.
  • Its last three reported values are $215.9 million in Q4 2025, $174.9 million for Q3 2025, and $172.9 million during Q2 2025.